> This Month's Featured Report from Drug Discovery Drug Repositioning Strategies: Innovative strategies to boost pipeline productivity 'Drug Repositioning Strategies' is a new report that provides in-depth analysis of leading pharma companies that are using novel technologies to reposition failed, marketed or reformulated compounds. This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them, enabling you to understand trends in the market and optimize your R&D pipeline.

Use this report to examine current approaches to drug repositioning and identify successful technologies and business models that can help your organization deliver enhanced clinical and commercial output.

Key issues examined in this report

• In spite of big pharma’s productivity crisis in developing new products, drug repositioning is currently being utilized in a limited capacity. How and when will this strategy drive up the ROI on compounds that failed as late as Phase 2 or 3?

• The realization that drugs often have activity in more than one indication is growing. New technologies, presented in this report, are being utilized successfully for indications discovery– the first
step of the drug repositioning process for both failed and marketed compounds.

• A large number of marketed drugs are due to come off patent in the next few years, providing a good supply of compounds for specialty pharma companies to test for activity on proprietary technology platforms

• Reformulation offers the potential for safer, more efficacious products that are easier for patients to use. This improves compliance with treatment regimes and increases patient satisfaction, while lowering the overall cost of treatment.


>> Published June 2007 >> Price $2875 >> More information >> Table of Contents >> eOrder >> Fax Order